Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study

Hui-Min Chang,1– 3 Pei-Yun Chou,4,5 Chen-Hsi Chou,2 Hung-Chin Tsai4– 6 1Department of Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; 2Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan; 3Department of Pha...

Description complète

Détails bibliographiques

Auteurs principaux:	Chang HM, Chou PY, Chou CH, Tsai HC
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2021
Sujets:	biktarvy bictegravir switching virological failure viremia Infectious and parasitic diseases RC109-216
Accès en ligne:	https://doaj.org/article/bc8b363815904e97b9c2de8da22d02e5
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!